Fall / Winter 2022 | Driving toward a Cure 3
“ The organizing principle for so much of what we do : to tackle the challenges with the highest risk , yet the greatest rewards .”
history , when we have contemplated such risks — from the alpha-synuclein tracer to the launch of our landmark clinical study Parkinson ’ s Progression Markers Initiative — we have asked ourselves : why should we be the ones to take this risk ? Why should we be the ones to drive it ?
Michael ’ s response has always come in the form of a question : “ If not us , who ?” That question governs every choice we make as we endeavor to address the unmet medical needs of people and families with PD . It will continue to motivate us until we reach our goal of eliminating Parkinson ’ s .
Since our inception , there have been many generous partners who have enabled us to pursue the boldest ideas to move PD research forward . Few have been as influential and extraordinary as the late Lily Safra — visionary philanthropist , MJFF Board member and chairwoman of the Edmond J . Safra Foundation — who passed away earlier this year . The following page provides just a snapshot of her transformative contributions that forever changed the course of Parkinson ’ s research and care .
We wouldn ’ t be able to drive discoveries toward a cure without you — our community , our critical partners in this mission . We are enormously grateful for your support in so many ways – contributing to research , engaging with our Parkinson ’ s resources , fostering collaboration and funding research . The power of community plus research is indisputable — and you ’ re proving that every day .
As we celebrate this milestone on the path to a new tool for the detection of Parkinson ’ s , we are clear-eyed about the work still to be done to find a cure . But we know through your help , anything is possible .
With gratitude ,
Debi Brooks CEO and Co-Founder